Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model

British Journal of Haematology

Volumn 120, Issue 1, 2003, Pages 27-35

  Stritzke, Jan ^a   Zunkel, Tim ^a   Steinmann, Jörg ^a   Schmitz, Norbert ^b   Uharek, Lutz ^c   Zeis, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Granulocyte macrophage colony stimulating factor (GM CSF); Idiotype vaccination; Interleukin 2 (IL 2); Multiple myeloma

Indexed keywords

CD8 ANTIGEN; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 2; M PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION; INOCULATION; MODEL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR; TUMOR RECURRENCE; TUMOR REJECTION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPES; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOPLASMS, EXPERIMENTAL; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0037219831     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.03930.x     Document Type: Article

References (24)

1. Bendandi, M., Gocke, C.D., Kobrin, C.G., Benkom, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L. & Kwak, L. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma. Nature Medicine, 5, 1171-1177.
2. Bianchi, A. & Massaia, M. (1997) Idiotypic vaccination in B-cell malignancies. Molecular Medicine Today, 10, 435-441.
3. Bogen, B., Munthe, L., Sollien, A., Hofgaard, P., Omholt, H., Dagnaes, F., Dembic, Z. & Lauritzsen, G.F. (1995) Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. European Journal of Immunology, 11, 3079-3086.
4. Cull, G., Durrant, L., Stainer, C., Haynes, A. & Russell, N. (1999) Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. British Journal of Haematology, 107, 648-655.
5. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Thielemans, F., Oberdan, L., Urbain, J. & Moser, M. (1994) Murine dendritic cells pulsed in vitro with tumour antigen induce tumour resistance in vivo. European Journal of Immunology, 24, 605-610.
6. Hotton, K.M., Khorsand, M., Hank, J.A., Albertini, M., Kim, K.M., Wilding, G., Salamat, M.S., Larson, M., Sondel, P. & Schiller, J.H. (2000) A phase Ib/II trial of granulocyte-macrophagecolony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: A case of fatal central nervous system thrombosis. Cancer, 88, 1892-1901.
7. Kwak, L.W., Young, H.A., Pennington, R.W. & Weeks, S.D. (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proceedings of the National Academy of Sciences of the United States of America, 93, 10972-10977.
8. Kwak, L.W., Pennington, R., Boni, L., Ochoa, A.C., Robb, R.J. & Popescu, M.C. (1998) Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. Journal of Immunology, 160, 3637-3641.
9. Li, Y., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L.W. & Lyerly, H.K. (2000) Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood, 96, 2828-2833.
10. Lim, S.H. & Bailey-Wood, R. (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer, 83, 215-222.
11. Lynch, R.G., Graff, R.J., Sirisinha, S., Simms, E.S. & Eisen, H.N. (1972) Myeloma proteins as tumor-specific transplantation antigens. Proceedings of the National Academy of Sciences of the United States of America, 69, 1540-1544.
12. Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M. & Pileri, A. (1999) Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 94, 673-683.
13. Österborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Rudén, U., Lefvert, A.-K., Holm, G. & Mellstedt, H. (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood, 91, 2459-2466.
14. Reichardt, V.L., Okada, C.Y., Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G. & Levy, R. (1999) Idio-type vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study. Blood, 93, 2411-2419.
15. Shimizu, K., Fields, R.C., Giedlin, M. & Mulé, J.J. (1999) Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proceedings of the National Academy of Sciences of the United States of America, 96, 2268-2273.
16. Sirisinha, S. & Eisen, H.N. (1971) Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proceedings of the National Academy of Sciences of the United States of America, 68, 3130-3155.
17. Stewart-Akers, A.M., Clairs, J.S., Tweardy, D.J. & McCarthy, S.A. (1993) Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. Blood, 81, 2671-2678.
18. Takahashi, K., Saito, S., Kamamura, Y., Katakawa, M. & Monden, Y. (2000) Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients. Immunology and Immunotherapy, 49, 537-543.
19. Timmerman, J.M. & Levy, R. (1999) Dendritic cell vaccines for cancer immunotherapy. Annual Reviews of Medicine, 50, 507-529.
20. Timmerman, J.M. & Levy, R. (2000) Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. Journal of Immunology, 164, 4797-4803.
21. Wen, Y.-J., Barlogie, B. & Yi, Q. (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma. Evidence for their capacity to lyse autologous primary tumor cells. Blood, 97, 1750-1755.
22. Zeis, M., Steinmann, J., Petrela, E., Hartung, G., Schmitz, N. & Uharek, L. (2001) Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice. Bone Marrow Transplantation, 27, 279-285.
23. Zeis, M., Frenzke, H., Schmitz, N., Uharek, L. & Steinmann, J. (2002a) Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice. Bone Marrow Transplantation, 29, 213-221.
24. Zeis, M., Zunkel, M., Steinmann, J., Schmitz, N. & Uharek, L. (2002b) Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin-2 against a murine myeloma. British Journal of Haematology, 117, 93-102.